In a Phase Ib clinical trial ( NCT01864655 ) in patients with mild-to-moderate AD, AZD0530 could achieve substantial CNS penetration through oral dosing at 100–125 mg [ 83 ], and later in a multicenter Phase IIa randomized clinical trial ( NCT02167256 ), it showed a trend for slowing the reduction of hippocampal volume and entorhinal thickness [ 84 ].
← all excerpts
The role of pathological tau in synaptic dysfunction in Alzheimer's diseases.
1
—
—